Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Bratisl Lek Listy ; 119(10): 619-624, 2018.
Article in English | MEDLINE | ID: mdl-30345768

ABSTRACT

PURPOSE:   Adiponectin is a protein stemming from adipose tissue and having strong anti-inflammatory properties. We aimed to assess the damage diminishing effects of recombinant adiponectin  (rAD) through NF-kB in the experimental acute pancreatitis  (AP) model. MATERIALS AND METHODS:   Acute pancreatitis was created by applying 50 µg/kg dose of intraperitoneal cerulean. The rats were randomised and divided into 3 groups as control, AP and rAD groups. Moreover, the rats in each group were divided into two sub-groups as 24th and 48th hour subgroups. rAD was injected in the study group intraperitoneally. Tissue and blood samples were taken after 24 and 48 hours. Histopathological assessment and NF-kB activity were investigated in pancreatic tissue. RESULTS:   Serum TNF-a, IL-1b and IL-6 levels were found to be statistically significant in the AP group compared to the rAD group in the 24th and 48th hour  (p < 0.05). Similarly, NF-kB activity was also found to be significant in the AP group both in the 24th and 48th hour  (p < 0.05). There were significant differences in the AP and the rAD groups histopathologically in terms of edema, inflammation, vacuolisation and necrosis  (p < 0.001). CONCLUSION:   rAD has significantly reduced NF-kB activity, cytokine levels and tissue damage  (Tab. 1, Fig. 1, Ref. 51).


Subject(s)
Adiponectin , NF-kappa B , Pancreatitis , Recombinant Proteins , Acute Disease , Adiponectin/pharmacology , Animals , Inflammation , NF-kappa B/drug effects , NF-kappa B/metabolism , Pancreas , Pancreatitis/drug therapy , Pancreatitis/immunology , Random Allocation , Rats , Recombinant Proteins/therapeutic use , Tumor Necrosis Factor-alpha
2.
Bratisl Lek Listy ; 119(3): 152-155, 2018.
Article in English | MEDLINE | ID: mdl-29536743

ABSTRACT

AIM: We aimed to study the effects of thymoquinone on erythrocyte deformability in an experimental model of sepsis given before or after the initiation of the sepsis model. METHOD: The animals were grouped as (n = 6) control, nigella sativa, sepsis, sepsis group with administration of nigella sativa before sepsis development and sepsis group with nigella sativa administration after sepsis development. Cecal ligation and puncture model (CLP) was used to induce sepsis in the animals. The thymoquinone was given 1 hour before or after the CLP in the study groups with a dose of 500 mg·kg(-1). Erythrocyte deformability and relative resistance was calculated. RESULT: Relative resistance was increased in the sepsis groups when compared to the control group (p < 0.0001). Deformability index was increased in the sepsis group when compared to the other groups (p < 0.0001 in all groups). Sepsis group with after nigella sativa groups deformability index was significantly different from the deformability index in control group (p = 0.002). The use of nigella sativa before the initiation of sepsis corrected the deformability index significantly and the results were comparable to the control group (p = 0.078). CONCLUSION: Thymoquinone administration before induction of CLP was observed to have protective effects on these alterations in CLP sepsis (Tab. 1, Fig. 1, Ref. 26).


Subject(s)
Benzoquinones/pharmacology , Erythrocyte Deformability/drug effects , Intestinal Perforation/blood , Sepsis/blood , Animals , Cecum , Disease Models, Animal , Ligation , Male , Nigella sativa , Rats
3.
Bratisl Lek Listy ; 116(4): 270-5, 2015.
Article in English | MEDLINE | ID: mdl-25773957

ABSTRACT

AIM: In the present study we aimed to determine the effect of an AT-II antagonist candesartan on pancreatic microcirculation in an experimental model of acute necrotizing pancreatitis. MATERIALS AND METHODS: There were five study groups with 10 animals in each. Pancreatitis was induced by intravenous infusion of cerulein and coadministration of glycodeoxycholate into biliopancreatic canal. Candesartan is given at 6th and 18th hour to the 24th and 48th hour groups, respectively. At 24th and 48th hours; following anaesthesia laparotomy was performed and laser Doppler flowmetry was performed in the pancreatic tissue of the animals. Following scarification blood samples were obtained for amylase, myeloperoxidase, IL-6 and tumour necrosis factor alpha. Tissue samples from the pancreas were obtained for histopathological analysis, endothelial cell apoptosis (TUNEL assay) and matrix metalloproteinase-9 immunohistochemistry. RESULTS: Pancreatic microcirculation was higher in the candesartan treated groups (p < 0.05). Myeloperoxidase, IL-6 and tumour necrosis factor alpha was found to be lower in the candesartan treated groups (p < 0.05). The pancreatic edema and inflammation were found to be reduced in the candesartan treated groups (p < 0.05). Endothelial apoptosis was found to be reduced by cadesartan treatment but it did not reach statistical significance (p > 0.05). Tissue matrix metalloproteinase -9 levels were found to be reduced with candesartan treatment (p < 0.05). CONCLUSION: Treatment with candesartan in the early phases of acute necrotizing pancreatitis effective on microcirculation of pancreatic tissue (Tab. 3, Fig. 6, Ref. 28).


Subject(s)
Benzimidazoles/pharmacology , Microcirculation/drug effects , Pancreas/blood supply , Pancreatitis, Acute Necrotizing/drug therapy , Tetrazoles/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Apoptosis/drug effects , Biphenyl Compounds , Disease Models, Animal , Female , Pancreas/drug effects , Pancreas/pathology , Pancreatitis, Acute Necrotizing/pathology , Pancreatitis, Acute Necrotizing/physiopathology , Rats , Rats, Sprague-Dawley
4.
J Endocrinol Invest ; 32(2): 147-9, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19411813

ABSTRACT

Neopterin production provides information about the extent of cellular immune activation. Measurement of neopterin levels may also provide predictive and prognostic information in patients with malignant thyroid diseases. In the present study, neopterin levels were investigated in patients with thyroid disorders (no.=68). Twenty-four patients had papillary thyroid cancers and the rest of them benign thyroid disorders. Results were compared with a healthy control group (no.=30). It was observed that there was a significant difference in neopterin levels between the control group and the thyroid disorders group (p<0.05). The mean neopterin levels in malignant and benign patients were also significantly different (p<0.05). Monitoring of urinary neopterin profile may be used in early diagnosis of papillary thyroid cancer. Neopterin seems to be a differential biomarker for malignant and benign thyroid disorders.


Subject(s)
Biomarkers/urine , Neopterin/urine , Thyroid Diseases/urine , Adult , Biomarkers, Tumor/urine , Female , Goiter, Nodular/urine , Hashimoto Disease/urine , Humans , Male , Middle Aged , Thyroid Neoplasms/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...